临床试验/NCT01209598

NCT01209598已完成2 期

A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

Memorial Sloan Kettering Cancer Center1 个研究点分布在 1 个国家目标入组 90 人开始时间: 2010年9月23日最近更新: 2017年11月6日

适应症

干预措施

试验速览

阶段: 2 期
状态: 已完成
发起方: Memorial Sloan Kettering Cancer Center
入组人数: 90
试验地点: 1
主要终点: Progression Free Survival at 12 Weeks

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to find out what effects, good and/or bad, Palbociclib (Ibrance) (formerly known as PD0332991) has on the patient and on the liposarcoma.

Palbociclib is an investigational drug. An investigational drug is a medication that has not been approved for marketing by the Food and Drug Administration (FDA). Palbociclib blocks a protein called CDK4 which is part of a pathway in liposarcoma cells that is over-active. The investigators hope that blocking CDK4 will shut down this pathway in the liposarcoma cells and stop tumors from growing. Palbociclib is an oral medication.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•A diagnosis of liposarcoma confirmed at MSKCC. Because myxoid / round cell liposarcoma does not have significant CDK4 amplification, patients with this subtype are not eligible.
•Metastatic and/or locally advanced or locally recurrent disease that is not surgically resectable, with evidence of disease progression, either clinically or radiographically, as determined by the investigator
•All patients must have measurable disease as defined by RECIST 1.
•Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >10 mm when measured by CT, MRI or caliper measurement by clinical exam; or >20 mm when measured by chest x-ray. Lymph nodes must be > 15 mm in short axis when measured by CT or MRI.
•A minimum of 1 prior systemic regimen for recurrent/metastatic disease. Note: This requirement does not apply to patients enrolled in the Expansion Cohort. The last dose of systemic therapy (include targeted therapies) must have been given at least 2 weeks prior to initiation of therapy. Patients receiving BCNU or mitomycin C must have received their last dose of such therapy at least 6 weeks prior to initiation of therapy.
•Patients with brain metastasis that have been treated with definitive surgery or radiation and have been clinically stable for 3 months are eligible.
•Age > or = 18 years.
•ECOG performance status 0 or
•Adequate organ and marrow function as defined below (ULN indicates institutional upper limit of normal):
•Absolute neutrophil count ≥ 1.5x109/L Hemoglobin ≥ 9.0 g/dL WBC ≥ 3.0x109/L Platelets ≥ 100x109/L Total bilirubin ≤ 1.5 x ULN except for patients with known Gilbert syndrome AST(SGOT)/ALT(SGPT) ≤ 3 x institutional ULN Serum creatinine ≤ 1.5 x ULN or Creatinine Clearance > 50 mL/min (calculated by Cockcroft-Gault method)QTc interval ≤ 470 msec
•Patients must not have current evidence of another malignancy that requires treatment.
•The effects of Palbociclib on the developing human fetus at the recommended therapeutic dose are unknown. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence). Women must not breast feed while on study.
•Ability to understand and the willingness to sign a written informed consent document.
•Ability to swallow intact Palbociclib capsules.
•Patients" tumors must express Rb, as assessed using an historical biopsy sample if available or a newly obtained tumor sample. Samples must demonstrate ≥1+ staining for Rb. Patients' tumors must also have evidence of CDK4 amplification by FISH. Note: This does not apply to patients enrolled in the Expansion Cohort.

排除标准

•Patients who have not recovered from adverse events of prior therapy to ≤ NCI CTCAEv4.0 Grade
•Patients receiving any other investigational agents.
•Patients who have received prior treatment with a selective CDK4 inhibitor
•History of allergic reactions attributed to compounds of similar chemical or biologic composition to Palbociclib.
•Uncontrolled intercurrent illness including, but not limited to, known ongoing or active infection, including HIV, active hepatitis B or C, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (specifically, atrial fibrillation or ventricular dysrhythmias except ventricular premature contractions), or psychiatric illness/social situations that would limit compliance with study requirements.
•Pregnant women and women who are breast-feeding.
•Patients with a history of long-QT syndrome or documented family history of long-QT syndrome. Patients who must remain on drugs that prolong the QT interval.
•Palbociclib is a substrate of CYP3A. Caution should be exercised when dosing Palbociclib concurrently with CYP3A inducers or inhibitors. Furthermore, patients who are taking concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4 should be switched to alternative medications to minimize any potential risk. A list of CYP3A4 substrates, inducers and/or inhibitors is provided in Appendix B. The following medications with strong potential for interaction are not allowed: indinavir nelfinavir ritonavir clarithromycin itraconazole ketoconazole nefazodone saquinavir telithromycin carbamazepine phenobarbital phenytoin pioglitazone rifabutin rifampin St. John's wort Troglitazone

研究组 & 干预措施

Palbociclib 200mg

Experimental

This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.

干预措施: Palbociclib 200mg (Drug)

Palbociclib 125mg

Experimental

干预措施: Palbociclib 125mg (Drug)

结局指标

主要结局

Progression Free Survival at 12 Weeks

时间窗: 12 weeks

PFS, defined as RECIST 1.1 (CR + PR + SD) when treated with Palbociclib

次要结局

Best Response(2 years)

研究者

发起方

Memorial Sloan Kettering Cancer Center

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

进行中（未招募）

1 期

EUCTR2013-001040-62-ATGBG Forschungs GmbH1,250

进行中（未招募）

1 期

EUCTR2013-001040-62-ESGerman Breast GBG Forschungsgesellschaft mbH1,250

进行中（未招募）

1 期

EUCTR2013-001040-62-FRGBG Forschungs GmbH1,100

进行中（未招募）

1 期

EUCTR2013-001040-62-DEGBG Forschungs GmbH1,250

进行中（未招募）

1 期

EUCTR2013-001040-62-GBGBG Forschungs GmbH1,250